The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy

Zhang, Tao; Wang, Jianyang; Wang, Daquan; Xu, Kuo; Wu, Lizhong; Wang, Xin; Wang, Wenqing; Deng, Lei; Liang, Jun; Lv, Jima; Hui, Zhouguang; Zhou, Zongmei; Feng, Qinfu; Xiao, Zefen; Chen, Dongfu; Wang, Lühua; Bi, Nan

doi:10.1016/j.jncc.2021.11.003

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies showed better efficacy of combined immunotherapy and chemoradiotherapy for cancer treatment 53 , 54 . Several clinical trial in mCRPC patients showed the benefits of combined chemotherapy and immunotherapy for prostate cancer therapy 55 , 56 .…”

Section: The Combination Of Prostate Cancer Vaccines and Other Treatm...mentioning

confidence: 99%

Current status and progress of the development of prostate cancer vaccines

Wang¹,

Zhou²,

Zhu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

At present, common treatments of prostate cancer mainly include surgery, radiotherapy, chemotherapy and hormone therapy. However, patients have high recurrence rate after treatment, and are prone to castration-resistant prostate cancer. Tumor vaccine is based on tumor specific antigen (TSA) and tumor associated antigen (TAA) to activate specific immune response of the body to cancer cells. With continuous maturity of tumor vaccine technology, different forms of prostate cancer vaccines have been developed, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines. In this review, we summarize current status and progress in the development of prostate cancer vaccines.

show abstract

Section: The Combination Of Prostate Cancer Vaccines and Other Treatm...mentioning

confidence: 99%

Current status and progress of the development of prostate cancer vaccines

Wang¹,

Zhou²,

Zhu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

show abstract

Curculigoside inhibits osteoarthritis <em>via</em> the regulation of NLRP3 pathway

Wang,

Liu,

Zhou

et al. 2023

Eur J Histochem

View full text Add to dashboard Cite

Osteoarthritis (OA) is characterized by degenerative articular cartilage. Nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3) plays an important role in inflammation. This study aims to investigate whether protective effects of curculigoside on OA are medicated by the regulation of NLRP3 pathway. Destabilization of the medial meniscus (DMM) was performed to build an OA mouse model. After surgery, OA mice were treated with curculigoside. Immunohistochemistry was conducted to evaluate OA cartilage. In addition, human chondrocytes were isolated and treated with curculigoside. The mRNA and protein expression of iNOS, MMP-9, NLRP3 was detected by PCR and Western blot analysis. Curculigoside inhibited mRNA and protein levels of iNOS and MMP-9 induced by DMM surgery in a dose-dependent manner. Furthermore, the expression of NLRP3, NF-κB and PKR was downregulated after curculigoside administration. Moreover, curculigoside reversed the effects of IL-1β on MMP-9, iNOS and type II collagen expression at mRNA and protein levels in human chondrocytes in a dose-dependent manner. In conclusion, curculigoside exhibits beneficial effect on cartilage via the inhibition of NLRP3 pathway.

show abstract

The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy

Cited by 2 publications

References 52 publications

Current status and progress of the development of prostate cancer vaccines

Current status and progress of the development of prostate cancer vaccines

Curculigoside inhibits osteoarthritis <em>via</em> the regulation of NLRP3 pathway

Contact Info

Product

Resources

About